CytoSorbents(CTSO)

Focus: CytoSorbents is a publicly traded biotechnology company specializing in blood purification therapy, primarily using its CytoSorb hemoadsorption device platform to address critical care indications including sepsis, cardiac surgery, and liver failure. The company operates at mid-cap scale with $36M in FY2025 revenue.

Gastroenterology Infectious Diseases Cardiovascular

Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

1-1 this month

Stable — net -1 jobs in 30d

0 added, 1 removed. Backfill posture.

Should You Work at CytoSorbents?

AI assessment

CytoSorbents offers unique technology exposure in a differentiated market but presents elevated financial and employment stability risk; best suited for candidates seeking niche clinical expertise and tolerance for early-stage company volatility.

Why Work Here

Rare blood purification technology platform with broad clinical applicability across gastroenterology, infectious disease, and cardiovascular indications

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$36M

Pipeline & Clinical Trials

CytoSorb 300 mL device

COVID-19

N/A

Clinical Trials (1)

NCT04391920Registry of CytoSorb Therapy in COVID-19 ICU Patients

N/A

Help build intelligence for CytoSorbents

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with established revenue ($36M FY2025) and commercial infrastructure, providing more stability than pre-revenue biotech

Pipeline spanning Phase 3 and Phase 4 programs with multiple indications (septic shock, cardiac surgery, acute pancreatitis) offering diverse clinical project exposure

Watch Out For

Severe financial distress: negative net income of -$20.7M in FY2025 despite revenue growth, with cash reserves declining from $14M to $3M YoY, raising runway concerns
Stock volatility and shareholder pressure: recent reverse split request (1-for-5 to 1-for-20) and Q1 2026 earnings miss indicate market confidence issues and potential future capital raises
No active job openings listed and minimal hiring activity visibility, suggesting limited growth hiring or potential restructuring ahead

Generated by Claude from CytoSorbents's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CytoSorb

Aneurysmal Subarachnoid Haemorrhage

N/A

Clinical Trials (1)

NCT05259514CytoSorb SAH Trial

N/A

Blood sampling and analysis

Acute Coronary Syndrome

N/A

Clinical Trials (1)

NCT04625764Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery

N/A

CytoSorb 300 mL device

Heart Failure

N/A

Clinical Trials (1)

NCT04596813Role of Cytosorb in Left Ventricular Assist Device Implantation

N/A

CytoSorb cytokine elimination

Inflammation

N/A

Clinical Trials (1)

NCT02606799Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy

N/A

Cytosorb® 300 ml

Septic Shock

N/A

Clinical Trials (1)

NCT04963920A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

N/A

CytoSorb-Therapy

Septic Shock

N/A

Clinical Trials (1)

NCT04013269Adjuvant Therapy With CytoSorb in Refractory Septic Shock

N/A

CytoSorb

Hemorrhage, Surgical

N/A

Clinical Trials (1)

NCT05077124Safe and Timely Antithrombotic Removal (STAR) Registry

N/A

CytoSorb® treatment

Acute on Chronic Liver Failure

N/A

Clinical Trials (1)

NCT05131230CytoSorb® in Patients With Acute on Chronic Liver Failure

N/A

CytoSorb

Septic Shock

N/A

Clinical Trials (1)

NCT05146336CytOSorb TreatMent Of Critically Ill PatientS Registry

N/A

CytoSorb

Infective Endocarditis

N/A

Clinical Trials (1)

NCT03945708Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?

N/A

Hemoadsorption

Cardiac Arrest

N/A

Clinical Trials (1)

NCT03632837HaemoAdsorption Nach Reanimation An ECMO

N/A

CytoSorb

Acute-On-Chronic Liver Failure

N/A

Clinical Trials (1)

NCT06079021COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device

N/A

Cytosorb

Cytokine Release Syndrome

N/A

Clinical Trials (1)

NCT04048434Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

N/A

CytoSorb

Elective Cardiac Surgery

N/A

Clinical Trials (1)

NCT02566525CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery

N/A

Sham comparator

Hemorrhage, Surgical

N/A

Clinical Trials (1)

NCT05093504Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)

N/A

Cytosorb Adsorber

Extracorporeal Circulation

N/A

Clinical Trials (1)

NCT03104179Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB

N/A

CytoSorb

Elective Cardiac Surgery

N/A

Clinical Trials (1)

NCT03384875CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

N/A

DrugSorb-ATR system

Hemorrhage, Surgical

N/A

Clinical Trials (1)

NCT04976530Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)

N/A

hemoadsorber for removal of cytokines

Infective Endocarditis

N/A

Clinical Trials (1)

NCT03266302Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis

N/A

Cytokine Adsorption

Septic Shock

N/A

Clinical Trials (1)

NCT04910893Cytokine Adsorption in Severe, Refractory Septic Shock

N/A

CytoSorb 300 mL device

Emergent Cardiothoracic Surgery

N/A

Clinical Trials (1)

NCT04131959Ticagrelor CytoSorb Hemoadsorption

N/A

CytoSorb Device

Rhabdomyolysis

PHASE_2

Clinical Trials (1)

NCT02111018Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis

Phase 2

CytoSorb

Elective Cardiac Surgical Interventions

PHASE_3

Clinical Trials (1)

NCT01879176Cytokine Removal in Cardiopulmonary Bypass Patients

Phase 3

CytoSorb hemoperfusion

Sepsis

PHASE_3

Clinical Trials (1)

NCT04643639Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis

Phase 3

CytoSorb

Pancreatitis, Acute

PHASE_4

Clinical Trials (1)

NCT03082469Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal

Phase 4

Interview Prep Quick Facts

Portfolio: 26 clinical trials

Top TAs: Gastroenterology, Infectious Diseases, Cardiovascular

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Therapeutic Area Focus

4 pipeline

4 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$36M15%

Net Income

-$21M

Cash

$3M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

No recent layoff announcements disclosed; however, reverse split request and earnings miss suggest potential organizational restructuring under evaluation.

Absence of disclosed warns and FDA warnings is positive, but financial distress and reverse split signal hidden restructuring risk; employment security is low without major financing or clinical wins.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Impact of extracorporeal circuits on systemic drug levels - a scoping review.

Journal of anesthesia, analgesia and critical care

2026

PMID:42116106

The international, prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients.

Journal of anesthesia, analgesia and critical care

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

CytoSorbents(CTSO)

Should You Work at CytoSorbents?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · CytoSorbents(10)

Open Jobs (1)

Assistant Financial and Reporting Controller

Financials (FY2025)

Hiring Trend

Risk Signals

Research Publications(10)